You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博騰股份(300363.SZ):擬與居年豐、博英匯及杜金剛共設一家合資公司 探索搭建海外創新藥引入服務
格隆匯 12-08 20:49

格隆匯 12 月 8日丨博騰股份(300363.SZ)公佈,為建立健全公司CDMO製藥服務平台,實現“讓好藥更早惠及大眾”的長遠使命,公司擬使用自有資金人民幣400萬元與控股股東、實際控制人之一居年豐以及重慶博英匯科技服務有限公司(“博英匯”)、杜金剛共同出資設立一家合資公司,主要致力於結合中國市場需求,探索搭建海外創新藥引入服務,專注於全球創新醫藥產品和技術的合作與引進,從全球範圍內為中國製藥企業篩選引進優質的創新藥項目,豐富中國製藥企業的創新藥研發項目管線。通過參與海外創新藥引入服務的佈局,公司未來將逐步實現為客户提供全面一體化的研發、生產及產品、技術引入服務解決方案,有利於協同公司獲得更全面的客户羣體,幫助公司構建對全球新藥發展趨勢的洞察力,更好地幫助客户實現全生命週期的藥物管理。

此次交易的共同出資人之一居年豐系公司控股股東、實際控制人之一,以及公司董事長兼總經理,共同出資人博英匯系居年豐先生所控制的企業,根據《深圳證券交易所創業板股票上市規則》及相關規定,居年豐屬於公司的關聯自然人,博英匯屬於公司的關聯法人,此次交易構成關聯交易。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account